<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; George</title>
	<atom:link href="http://www.tapanray.in/tag/george/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma Stakeholder Sentiment: Back to Square One?</title>
		<link>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-stakeholder-sentiment-back-to-square-one</link>
		<comments>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/#comments</comments>
		<pubDate>Mon, 28 May 2018 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[guru]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Marjin]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[maximizing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[non-profit]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sentiment]]></category>
		<category><![CDATA[socializing]]></category>
		<category><![CDATA[square]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8965</guid>
		<description><![CDATA[Is it fair to push out the core purpose of an important process, or rather a mission, unfairly? Whether we like it or not, it happened that way, over a period of time. Way back on December 01, 1950, George W. &#8230; <a href="http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Stakeholder-Mix Has Changed, But Pharma Marketing Has Not</title>
		<link>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-stakeholder-mix-has-changed-but-pharma-marketing-has-not</link>
		<comments>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/#comments</comments>
		<pubDate>Mon, 13 Jun 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[captains]]></category>
		<category><![CDATA[category]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[multi-stakeholder]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[pipeline]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recasting]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[serving]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7670</guid>
		<description><![CDATA[“We try never to forget that medicine is for the people. It is not for profit. Profits follow, and if we have remembered that, they never fail to appear.” In 1952, George Wilhelm Herman Emanuel Merck, the then President of &#8230; <a href="http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does India Believe in Two Different Drug Quality standards?</title>
		<link>http://www.tapanray.in/does-india-believe-in-two-different-drug-quality-standards/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-india-believe-in-two-different-drug-quality-standards</link>
		<comments>http://www.tapanray.in/does-india-believe-in-two-different-drug-quality-standards/#comments</comments>
		<pubDate>Wed, 28 May 2014 07:33:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bossidy]]></category>
		<category><![CDATA[Charan]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Larry]]></category>
		<category><![CDATA[Margaret]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ram]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5458</guid>
		<description><![CDATA[“Maintain and sharpen your intellectual honesty so that you’re always realistic. See things as they are, not way you want them to be.” The above profound statement is what the Management Guru Ram Charan made in his book titled, ‘Execution: &#8230; <a href="http://www.tapanray.in/does-india-believe-in-two-different-drug-quality-standards/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-india-believe-in-two-different-drug-quality-standards/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>George Washington University Law School&#8217;s &#8220;The India Project&#8221; &#8211; Arguments and Counter Arguments</title>
		<link>http://www.tapanray.in/george-washington-university-law-schools-the-india-project-arguments-and-counter-arguments/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=george-washington-university-law-schools-the-india-project-arguments-and-counter-arguments</link>
		<comments>http://www.tapanray.in/george-washington-university-law-schools-the-india-project-arguments-and-counter-arguments/#comments</comments>
		<pubDate>Mon, 07 Jun 2010 00:30:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Arguments]]></category>
		<category><![CDATA[CII]]></category>
		<category><![CDATA[counter]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[judge]]></category>
		<category><![CDATA[judiciary]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[Washington]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=418</guid>
		<description><![CDATA[Recently we witnessed yet another huge controversy on the &#8216;IP Summit&#8217; organized by the George Washington University Law School (GWULS), USA. It was alleged that this summit supported by law firms, some pharmaceutical companies and others, was intended to influence &#8230; <a href="http://www.tapanray.in/george-washington-university-law-schools-the-india-project-arguments-and-counter-arguments/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/george-washington-university-law-schools-the-india-project-arguments-and-counter-arguments/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
